Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NY-ESO-1 Specific TCR Gene-Transduced T Cells (TBI-1301) in Solid Tumors
jRCT2080222844Phase 1Completed
- Sponsor
- Mie University, Aichi Medical University, Keio University, National Cancer Center Hospital East, National Cancer Center Hospital, National Hospital Organization Nagoya Medical Center
- Start
- May 2015
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-NY-ESO-1 TCR-T in Nonhematologic neoplasms (2 cohorts), sponsored by Mie University, Aichi Medical University, Keio University, National Cancer Center Hospital East, National Cancer Center Hospital, National Hospital Organization Nagoya Medical Center. Primary endpoint: Primary safety and tolerability of TBI-1301. Started May 2015; status: completed.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222844.